Dexcom announced on Tuesday a man-made intelligence feature for its Stelo continuous glucose monitor that provides users personalized insight into the impact of meals, sleep and activity on their glucose levels. It's the primary iteration of a brand new generative AI platform the corporate has been constructing Google Cloud.
Stelo is an over-the-counter CGM that pierces the skin to measure blood sugar levels in real time. The sensor was launched in August and might be utilized by any adult who doesn’t take insulin.
The report reflects Dexcom's efforts to make Stelo more personalized and interesting for consumers as the corporate works to enter a brand new market.
“The main feedback we're getting is that users want to see more,” said Jake Leach, chief operating officer at Dexcom, in an interview with CNBC. “They are making an investment and carrying the product, and they want to be able to get the most value out of all the data they generate.”
Dexcom uses Google's Gemini models and its Vertex AI platform as the muse for its latest AI offering. Vertex AI allows developers to construct applications that synthesize several types of data, which might be notoriously difficult in healthcare.
Leach said Dexcom can be exploring how its generative AI platform may very well be utilized in its other CGM products, but the corporate is taking a very cautious approach due to patients' reliance on it to forestall medical emergencies.
“I really felt like Stelo was the right place for it for the first time,” he said.
An existing Insights report was already available to users within the Stelo app, nevertheless it followed a more standard template format each week. Dexcom expects the AI-generated report might be more priceless to users since it is personalized, Leach said.
If there may be per week wherein a user doesn’t exercise enough, for instance after eating, the report includes relevant suggestions and academic materials to assist.
Stelo's AI reports don’t provide users with medical advice, although Dexcom used a U.S. Food and Drug Administration AI framework to guide development of the feature, Leach said. The FDA approved Stelo in March.
Ultimately, Dexcom wants to make use of its generative AI platform to offer users with real-time feedback somewhat than simply weekly reports. The company can be exploring how the technology could function a predictive indicator of potential problems, just like the check engine light on a automotive.
“It gives you a sense of what might be going on and gives you recommendations on where you should go for further advice,” said Chris Sakalosky, vice chairman of strategic industries at Google Cloud, in an interview with CNBC.
Dexcom's updated weekly report was rolled out to Stelo users this week.
image credit : www.cnbc.com